Forsare Carina, Vistrand Sara, Ehinger Anna, Lövgren Kristina, Rydén Lisa, Fernö Mårten, Narbe Ulrik
Division of Oncology, Department of Clinical Sciences Lund, Lund University, SE-223 81 Lund, Sweden.
Department of Oncology, Växjö Central Hospital, SE-352 34 Växjö, Sweden.
Cancers (Basel). 2022 Feb 14;14(4):941. doi: 10.3390/cancers14040941.
Previous studies have shown that high intratumoral stromal content is associated with a worse prognosis in breast cancer, especially in the triple-negative subtype. However, contradictory results have been reported for estrogen-receptor-positive (ER+) breast cancer, indicating that the prognostic role of intratumoral stromal content may be subtype-dependent. In this study, we investigated the importance of intratumoral stromal content for breast cancer-specific mortality (BCM) in a well-defined subgroup ( = 182) of ER+/human-epidermal growth-factor-receptor-2 negative (HER2-) invasive lobular breast cancer (ILC). The intratumoral stromal content was assessed on hematoxylin-eosin-stained whole sections and graded into high stroma (>50%) or low stroma (≤50%). A total of 82 (45%) patients had high-stroma tumors, and 100 (55%) had low-stroma tumors. High-stroma tumors were associated with a lower Nottingham histological grade, low Ki67, and a luminal A-like subtype. After a 10-year follow-up, the patients with high-stroma tumors had a lower BCM (HR: 0.43, 95% CI: 0.21-0.89, = 0.023) in univariable analysis. Essentially the same effect was found in both the multivariable analysis (10-year follow-up) and univariable analysis (25-year follow-up), but these findings were not strictly significant. In ER+/HER2- ILC, high intratumoral stromal content is an easily assessable histological indicator of a good prognosis.
既往研究表明,肿瘤内基质含量高与乳腺癌预后较差相关,尤其是三阴性亚型。然而,雌激素受体阳性(ER+)乳腺癌却报道了相互矛盾的结果,这表明肿瘤内基质含量的预后作用可能具有亚型依赖性。在本研究中,我们在一个明确界定的ER+/人表皮生长因子受体2阴性(HER2-)浸润性小叶癌(ILC)亚组(n = 182)中,研究了肿瘤内基质含量对乳腺癌特异性死亡率(BCM)的重要性。肿瘤内基质含量通过苏木精-伊红染色的全切片进行评估,并分为高基质(>50%)或低基质(≤50%)。共有82例(45%)患者患有高基质肿瘤,100例(55%)患有低基质肿瘤。高基质肿瘤与较低的诺丁汉组织学分级、低Ki67以及管腔A型亚型相关。经过10年随访,单因素分析显示高基质肿瘤患者的BCM较低(HR:0.43,95%CI:0.21-0.89,P = 0.023)。在多因素分析(10年随访)和单因素分析(25年随访)中均发现了基本相同的效应,但这些结果并不具有严格的显著性。在ER+/HER2- ILC中,肿瘤内基质含量高是预后良好的一个易于评估的组织学指标。